Avutometinib Potassium 0.8 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.8 mg

Reference Brands: Avmapki (USA), Fakzynja (USA)

Category: Oncology Cancer Care

Avutometinib 0.8 mg capsules, an oral RAF/MEK clamp used with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. For hospital pharmacies and importers arranging named-patient supply.

Product Description:

Avutometinib is an oral RAF/MEK clamp, a kinase inhibitor that holds RAF and MEK together in an inactive complex so the MAPK growth signal cannot pass down the chain. Unlike classic MEK inhibitors, it also stops RAF from switching MEK back on, an escape route that matters in KRAS-driven tumours. It is a potassium salt in 0.8 mg capsules. The 200 mg figure shown with it belongs to defactinib, a focal adhesion kinase inhibitor tablet packed and taken alongside it.

The pairing holds accelerated approval in the United States for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic treatment. Avutometinib is taken twice a week and defactinib twice a day, for three weeks of every four-week cycle, so a dosing calendar helps. Eye disorders, including blurred vision, are a known effect, and eye examinations are scheduled before and during use. Rash, raised liver enzymes and raised creatine phosphokinase are watched for. Both drugs can harm an unborn child.

Sourcing notes. This is a newly approved innovator therapy with very narrow registration, so most demand moves through named-patient or special-access import against an oncologist's prescription. Make clear whether you need the co-pack or the capsules alone, since the regimen is built on both. Keep capsules in the original container as the carton directs. Ask for the batch CoA, a traceable chain back to the authorisation holder, serialised packs with the approved leaflet and the import licence your regulator issues for unregistered medicines. Pharmacy teams apply their usual precautions for oral anticancer drugs.